Anavex Life Sciences Corp (AVXL)

[Tom_Green]

Yeah that's what they should have done from the beginning in stead of trying to rush the data for the CTAD conference. Maybe it was a way to pressure the CRO to work through the data faster but it bit them badly this time. They could have presented the data at a conference after the topline was released with nice scientific fanfare for the academicians but the initial release should have been crisp and clear. The management got their priorities mixed up. Not good.

I hope the patient group who titrated up to 50mg and stayed there has a sufficiently high effect to reach stat sig on its own. In the P2a the low dose had such a moderate effect that if the effect stands also in this trial then combining them together should really pull down the magnitude of the effectiveness of the high dose group.

BTW, I have been long this stock since 2015 and this marathon is not over yet. Maybe past the half way mark though.